Select Publications
Book Chapters
2022, 'Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer', in , Wiley, pp. 1 - 23, http://dx.doi.org/10.1002/9781119000822.hfcm105.pub2
,2022, 'Nonepithelial Ovarian Malignancies', in , Wiley, pp. 1 - 18, http://dx.doi.org/10.1002/9781119000822.hfcm106.pub2
,2020, 'The development of drug resistance through reversion mutation in BRCA genes in ovarian cancer', in Overcoming Ovarian Cancer Chemoresistance, pp. 43 - 53, http://dx.doi.org/10.1016/B978-0-12-819840-7.00013-3
,2020, 'Management of Rare Uterine Malignant Tumors', in Management of Endometrial Cancer, Springer International Publishing, pp. 277 - 312, http://dx.doi.org/10.1007/978-3-319-64513-1_19
,2017, 'Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer', in , Wiley, pp. 1 - 27, http://dx.doi.org/10.1002/9781119000822.hfcm105
,2017, 'Nonepithelial Ovarian Malignancies', in , Wiley, pp. 1 - 17, http://dx.doi.org/10.1002/9781119000822.hfcm106
,2014, 'Chemotherapy', in Berek and Hacker's Gynecologic Oncology: Sixth Edition, pp. 58 - 84
,2014, 'Epithelial ovarian, fallopian tube, and peritoneal cancer', in Berek and Hacker's Gynecologic Oncology: Sixth Edition, pp. 464 - 529
,2014, 'Germ cell and nonepithelial ovarian cancer', in Berek and Hacker's Gynecologic Oncology: Sixth Edition, pp. 530 - 559
,2014, 'Uterine cancer', in Berek and Hacker's Gynecologic Oncology: Sixth Edition, pp. 390 - 442
,2014, 'Response as a measure of treatment efficacy in clinical trials: Should recist be abandoned?', in Controversies in the Management of Gynecological Cancers, pp. 91 - 100, http://dx.doi.org/10.1007/978-0-85729-910-9_9
,2011, 'Ovarian, Fallopian Tube and Peritoneal Cancer', in Berek JS (ed.), Berek and Novak's Gynecology, edn. 15th, Royal College of Obstetricians and Gynaecologists, UK, pp. 1350 - 1427
,2011, 'Squamous Cell Carcinomas Arising From Dermoids', in Reed N; Green JA; Gershenson DM; Siddiqui N; Connor R (ed.), Rare and Uncommon Gynecological Cancers, Springer, USA, pp. 131 - 134
,2010, 'Breast Disease: A Gynecologic Perspective', in Hacker &amp Moore's Essentials of Obstetrics and Gynecology, Elsevier, pp. 326 - 331, http://dx.doi.org/10.1016/b978-1-4160-5940-0.00029-1
,1997, 'Stage IIC ovarian cancer which is completely resected. In expert consultations in gynecological cancers.', in Stage IIC ovarian cancer which is completely resected. In expert consultations in gynecological cancers., edn. Original, Mercel Dekker, New York, pp. 263 - 270
,Journal articles
2024, 'Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual disease', npj Genomic Medicine, 9, http://dx.doi.org/10.1038/s41525-024-00395-y
,2024, 'Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over', Gynecologic Oncology, 187, pp. 221 - 226, http://dx.doi.org/10.1016/j.ygyno.2024.05.021
,2024, 'Hidden in plain sight – Survival consequences of baseline symptom burden in women with recurrent ovarian cancer', Gynecologic Oncology, 185, pp. 128 - 137, http://dx.doi.org/10.1016/j.ygyno.2024.02.025
,2024, 'Identifying optimized assessment of nerve damage during chemotherapy.', Journal of Clinical Oncology, 42, pp. 12016 - 12016, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.12016
,2024, 'Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial', Translational Oncology, 43, http://dx.doi.org/10.1016/j.tranon.2024.101914
,2024, 'Rates of paclitaxel hypersensitivity reactions using a modified Markman's infusion protocol as primary prophylaxis.', Support Care Cancer, 32, pp. 292, http://dx.doi.org/10.1007/s00520-024-08460-z
,2024, 'Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g BRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer', Journal of Clinical Oncology, 42, pp. 1288 - 1300, http://dx.doi.org/10.1200/JCO.23.01214
,2024, 'Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor', Journal of Clinical Oncology, 42, pp. 1301 - 1310, http://dx.doi.org/10.1200/JCO.23.01182
,2024, 'Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial', European Journal of Cancer, 200, http://dx.doi.org/10.1016/j.ejca.2024.113580
,2024, 'Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer', British Journal of Cancer, 130, pp. 425 - 433, http://dx.doi.org/10.1038/s41416-023-02528-z
,2024, '8P Biomarkers to predict chemotherapy response in low-grade serous ovarian carcinoma', ESMO Open, 9, pp. 103508 - 103508, http://dx.doi.org/10.1016/j.esmoop.2024.103508
,2024, 'Plasma Lipidomic Profiling Identifies Elevated Triglycerides as Potential Risk Factor in Chemotherapy-Induced Peripheral Neuropathy.', JCO Precis Oncol, 8, pp. e2300690, http://dx.doi.org/10.1200/PO.23.00690
,2024, 'Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized Trials.', JCO Precis Oncol, 8, pp. e2300296, http://dx.doi.org/10.1200/PO.23.00296
,2023, 'Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer.', Sci Rep, 13, pp. 21884, http://dx.doi.org/10.1038/s41598-023-48153-x
,2023, 'Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial', British Journal of Cancer, 129, pp. 797 - 810, http://dx.doi.org/10.1038/s41416-023-02349-0
,2023, 'Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival', Cancer Medicine, 12, pp. 16142 - 16162, http://dx.doi.org/10.1002/cam4.6272
,2023, 'Association of Protein Intake with Recurrence and Survival Following Primary Treatment of Ovarian Cancer', American Journal of Clinical Nutrition, 118, pp. 50 - 58, http://dx.doi.org/10.1016/j.ajcnut.2023.05.002
,2023, 'Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study', Gynecologic Oncology, 174, pp. 213 - 223, http://dx.doi.org/10.1016/j.ygyno.2023.05.013
,2023, 'Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response: A translational sub-study of the REZOLVE (ANZGOG-1101) clinical trial.', Journal of Clinical Oncology, 41, pp. 5561 - 5561, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5561
,2023, 'Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: An international multicentre analysis', CMAJ. Canadian Medical Association Journal, 66, pp. E310 - E320, http://dx.doi.org/10.1503/cjs.017020
,2023, 'Molecular tumor profiling and therapy selection in advanced gynecological cancers: A retrospective cohort analysis from the Australian Molecular Screening and Therapeutics (MoST) Program.', Journal of Clinical Oncology, 41, pp. 5526 - 5526, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5526
,2023, 'Plasma lipidomic profiling of chemotherapy-induced peripheral neuropathy.', Journal of Clinical Oncology, 41, pp. 3031 - 3031, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3031
,2023, 'Quality of life (QoL) in patients with recurrent ovarian clear cell carcinoma (rOCCC) receiving durvalumab (D) versus physician’s choice chemotherapy (PCC) in the randomized phase II MOCCA/APGOT-OV2/GCGS-OV3 trial.', Journal of Clinical Oncology, 41, pp. e17564 - e17564, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e17564
,2023, 'The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study', Gynecologic Oncology, 173, pp. 130 - 137, http://dx.doi.org/10.1016/j.ygyno.2023.03.018
,2023, 'Common analgesics and ovarian cancer survival: the Ovarian cancer Prognosis And Lifestyle (OPAL) Study', Journal of the National Cancer Institute, 115, pp. 570 - 577, http://dx.doi.org/10.1093/jnci/djac239
,2023, 'Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma', Translational Oncology, 31, http://dx.doi.org/10.1016/j.tranon.2023.101638
,2023, 'Abstract CT033: Safety, pharmacokinetics, and antitumor activity findings from a phase 1b, open-label, dose-escalation and expansion study investigating RAF dimer inhibitor lifirafenib in combination with MEK inhibitor mirdametinib in patients with advanced or refractory solid tumors', Cancer Research, 83, pp. CT033 - CT033, http://dx.doi.org/10.1158/1538-7445.am2023-ct033
,2023, 'Exercise during CHemotherapy for Ovarian cancer (ECHO) trial: Design and implementation of a randomised controlled trial', BMJ Open, 13, http://dx.doi.org/10.1136/bmjopen-2022-067925
,2023, 'The impact of coding germline variants on contralateral breast cancer risk and survival', American Journal of Human Genetics, 110, pp. 475 - 486, http://dx.doi.org/10.1016/j.ajhg.2023.02.003
,2023, 'Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes', JNCCN Journal of the National Comprehensive Cancer Network, 21, pp. 125 - 132, http://dx.doi.org/10.6004/jnccn.2022.7074
,2023, 'Physical activity behaviors in cancer survivors treated with neurotoxic chemotherapy', Asia-Pacific Journal of Clinical Oncology, 19, pp. 243 - 249, http://dx.doi.org/10.1111/ajco.13834
,2023, 'CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis from the VELIA/GOG-3005 Study', Journal of Clinical Oncology, 41, pp. 107 - 116, http://dx.doi.org/10.1200/JCO.22.00430
,2023, 'Getting the MOST out of follow-up: A randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer', International Journal of Gynecological Cancer, http://dx.doi.org/10.1136/ijgc-2021-002999
,2023, 'Overall Survival with Maintenance Olaparib at a 7-Year Follow-up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial', Obstetrical and Gynecological Survey, 78, pp. 25 - 27, http://dx.doi.org/10.1097/OGX.0000000000001120
,2023, 'Profiling the immune landscape in mucinous ovarian carcinoma', Gynecologic Oncology, 168, pp. 23 - 31, http://dx.doi.org/10.1016/j.ygyno.2022.10.022
,